DA
TEVA icon

DSC Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

DSC Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-292,500
Closed -$2.98M – 37
2023
Q3 		$2.98M Sell
292,500
-17,500
-6% -$163K 3.83% 10
2023
Q2 		$2.33M Buy
310,000
+130,000
+72% +$1.05M 3.5% 8
2023
Q1 		$1.59M Buy
+180,000
New +$1.78M 1.39% 9
2022
Q4 		– Sell
-90,000
Closed -$726K – 82
2022
Q3 		$726K Buy
+90,000
New +$796K 0.75% 24

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DSC Advisors's TEVA Position: Q4 2023 in Review

DSC Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 292,500 shares — an estimated $2.98M sold.

DSC Advisors first reported a position in TEVA in Q3 2022 and held it in 4 quarters. The position peaked at $2.98M in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • DSC Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • DSC Advisors sold 292,500 Teva Pharmaceuticals shares in Q4 2023, an estimated $2.98M.
  • DSC Advisors first reported a position in Teva Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • DSC Advisors's Teva Pharmaceuticals position peaked at $2.98M in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on DSC Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.